2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
13
Neoplasms
12
Brain Neoplasms
6
Prostatic Neoplasms
5
Neoplasm Metastasis
4
Lung Neoplasms
4
Sarcoma
3
Multiple Myeloma
3
Melanoma
3
Glioblastoma
3
Gastrointestinal Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Thymus Neoplasms
2
Stomach Neoplasms
2
Sarcoma, Synovial
2
Rectal Neoplasms
2
Pain
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neuroendocrine Tumors
2
Nasopharyngeal Carcinoma
2
Mesothelioma
2
Liposarcoma
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Fatigue
2
Colorectal Neoplasms
2
Interventions
Gemcitabine
157
Cisplatin
117
pembrolizumab
81
Cystectomy
46
Nivolumab
42
Carboplatin
42
Paclitaxel
41
Mitomycin
41
Docetaxel
39
atezolizumab
33
Magnetic Resonance Spectroscopy
33
Radiotherapy
31
durvalumab
30
avelumab
26
BCG Vaccine
26
Specimen Handling
25
Cystoscopy
24
enfortumab vedotin
23
Doxorubicin
23
Fluorouracil
20
Methotrexate
17
Vinblastine
16
Standard of Care
15
Ipilimumab
14
Filgrastim
14
5-aminolevulinic acid hexyl ester
14
Transurethral Resection of Bladder
13
Surgical Procedures, Operative
13
Sunitinib
13
Biopsy
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Quality of Life
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled